ClinicalTrials.gg
RecruitingNCT07802340Updated Sep 23, 2026

Efficiency of Asiaticoside as Intracanal Medication in Revascularization Process

An interventional study of Intracanal medication in Immature Permanent Teeth With Open Apex and Pulp Necrosis, sponsored by Mansoura University. Recruiting at 1 site in Egypt. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 43 studies in Dental Pulp Necrosis with a site in Egypt — 12 open to participants now, 16 under way, 1 of them phase 3. Dental Pulp Necrosis · Egypt.

Planned enrollment
38th of 43
20 · median 40
Started
2026
with 6 others
No phase
31 of 43
9 open now
Primary completion
2027-02
later than 11 of 15 live
Registered
42nd of 43
by date
Lead sponsor
7 of 43
Mansoura University

Among the 43 studies in Dental Pulp Necrosis with a site in Egypt, this one is the 38th largest by planned enrollment, is one of 7 that started in 2026, is one of 31 with no phase, reaches primary completion later than 11 of the 15 other live ones, and was the 42nd registered.

Dental Pulp Necrosis

157 studies on the registry are indexed under Dental Pulp Necrosis; 44 are open to participants now.

Browse Dental Pulp Necrosis studies →

Open to participants now

12 of the 43 studies in Dental Pulp Necrosis with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 15 Dental Pulp Necrosis studies recruiting now, 6 (40%) set no upper age limit and 7 (47%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Dental Pulp Necrosis with a site in Egypt, or all of them as a file.
02

Study summary

This study assess the ability of Asiaticoside based Intracanal medication compared to the commonly used Intracanal medicament ( calcium hydroxide Ca(OH) 2) on the outcome of the revascularization process in immature permanent teeth with pulp necrosis

03

Conditions studied

  • Immature Permanent Teeth With Open Apex
  • Pulp Necrosis

Browse trials for

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both gender
  • patients having permanent anterior teeth with necrotic pulp and immature apex
  • Good general health
  • pulp space not needed for post and core

Exclusion criteria

Exclusion Criteria:

  • Radiographic identification of root fracture or abnormality
  • Uncooperative patients
  • Root resorption (internal or external)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Asiaticoside

    Procedure: Intracanal medication

  • Experimental
    Calcium hydroxide

    Procedure: Intracanal medication

Interventions

  • ProcedureIntracanal medication

    Intracanal Medication for 3 weeks in Revascularization Process

06

What researchers measure

Primary outcomes

  1. Increase In Root Length

    Radiographic increase in root length ( Millimeters(mm))

    Time frame: 12 monthsl

  2. Increase In Dentinal Wall Thickness

    Radiographic increase in dentinal wall thickness measured using digital image analysis (Millimeters(mm))

    Time frame: 12 months

  3. Periapical Bone Formation

    Radiographic evidence of periapical bone formation

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.

Of 66 non-industry interventional studies with no phase under Dental Pulp Necrosis, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 4 months is below that.

Counting every sponsor, half of 67 studies reached it within 15 months; a quarter within 9 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 3, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2028
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07802340
Responsible party
Sponsor
First posted
Sep 3, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 23, 2026

Study contacts

Maha Baher Hassan
Contact
Mahabaher23@gmail.com
01007987417

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion